Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

ESMO 24: Genmab Has AbbVie In Its Sights As Rina-S Shines In Ovarian Cancer

17 Sep 2024

• By Kevin Grogan

Genmab Office Copenhagen - close up — • Source: Genmab

Related Content

Genmab's Growth Strategy: Embracing A ‘Super Rational, Data-Driven' Mindset

13 Mar 2024

Genmab Adds To Sector ADC Buying Spree With $1.8bn ProfoundBio Acquisition

03 Apr 2024

ImmunoGen Transitions To Commercial Stage With Elahere Launch

15 Nov 2022

Sutro Works Toward A Better Ovarian Cancer ADC

04 Jul 2024

AbbVie Spends $10bn On ImmunoGen To Improve Chances In ADC Space

30 Nov 2023

Related Companies

Genmab A/S

ProfoundBio (Suzhou) Co., Ltd.

ImmunoGen, Inc.

AstraZeneca PLC

Sutro Biopharma, Inc.

Pfizer Inc.

Johnson & Johnson

Additional Topics

Clinical Trials Research & Development Strategy Women's Health ESMO Cancer BioPharmaceutical

More from ESMO

More from Leadership

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.